KS-KCAS
KCAS Bioanalytical and Biomarker Services (KCAS), a leading bioanalytical contract research organization (CRO), backed by Vitruvian Partners, closed the purchase of Active Biomarkers, located in Lyon, France. Active Biomarkers is a renowned assay development and specialty bioanalytical laboratory with expertise in oncology, infectious disease, inflammation and neurodegenerative disorders. Financial terms were not disclosed. Formerly owned by its management team and Turenne Santé fund, Active Biomarkers operates in a new, state-of-the-art facility in Lyon, France with significant expansion opportunities. This transaction adds valuable bioassay and cellular analysis expertise as well as European capacity to support customers globally as KCAS continues to advance its mission of providing high quality bioassay services to the biotech and pharmaceutical industries. The acquisition of Active Biomarkers is the second in 2022 by KCAS. FlowMetric, a leading flow cytometry and cellular analysis CRO, joined KCAS in early 2022. The Lyon site adds to KCAS and FlowMetric’s existing facilities in Kansas, Philadelphia and Milan, Italy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220912005063/en/
Active Biomarkers building in Lyon, France (Photo: Business Wire)
John Bucksath, CEO of KCAS, stated “We are delighted to partner with the Active Biomarkers team, accelerating our combined offering to support the customers we serve globally. The combined expertise and capacity of KCAS, FlowMetric, and Active Biomarkers is unique. The high-quality, science-first and client-centric culture we all share is key to our commitment to become the CRO partner of choice for the global pharma and biopharma industries. KCAS has embarked on significant investments, including a purpose-built 70,000 sq. ft. facility in Kansas City and a 26,000 sq. ft. facility in Pennsylvania, and accelerating our international footprint through acquisitions. We continue to attract the industry’s top scientific talent and focus on outstanding science and customer service. With our investors, Vitruvian Partners, we are optimally positioned to invest in our people and deliver world-class services for our growing client base. The acquisition of Active Biomarkers gives our combined clients access to further scientific expertise and support in both markets regionally and internationally.”
Marc Essodaigui, CEO of Active Biomarkers, comments, “Our entire team is thrilled about the new partnership with KCAS and the combined organizations’ outlook. This combination will allow us to provide even more comprehensive, best-in-class services for the biopharma and life sciences sector. The KCAS’ alliance, backed by a leading world-class growth investor, will provide us with the support and growth to expand our technological expertise, capacity, and geographical footprint.”
Sophie Bower-Straziota, Partner at Vitruvian Partners, comments, “Active Biomarkers has built a strong reputation in Europe founded in scientific excellence. The company fits with our investment strategy of backing best-in-class operations offering services to a market with strong tailwinds and internationalization opportunities. The acquisition of Active Biomarkers by KCAS builds on the excellent foundation KCAS has built in the US and supports the increasingly international needs of the company’s growing pharmaceutical and biotech clients. As the drug development market continues to evolve, we will continue to support investment in scientific capabilities, broadening geographical reach, providing the resources to scale the business, and making strategic acquisitions.”
About KCAS - KCAS is a rapidly growing company that provides comprehensive GLP compliant development services from early discovery support through product registration and beyond. One of only a select few CROs offering both large and small molecule development with extensive capabilities and expertise, KCAS provides a truly differentiated approach to its clients who are looking for both scientific expertise and excellent customer service. KCAS is headquartered in Olathe, Kansas – the Kansas City metro area and employs more than 300 employees. Website: KCASBio.com.
About Active Biomarkers – Founded in 2011, Active Biomarkers is an integrated bioanalytical laboratory offering a wide range of services, including PK, immunogenicity, soluble and cellular biomarker analyses for clinical studies. Operating in state-of-the-art BSL2 facilities, GCLP accredited and ISO 9001:2015 certified, the company has a unique track-record in the development, validation, and implementation of analytical methods. Its expert team has supported hundreds of studies in multiple therapeutic areas: oncology, infectious diseases, inflammatory pathologies, and neurodegenerative diseases. Beyond its state-of the-art flow cytometry and ELISpot capabilities, Active Biomarkers offers the broadest panel of immunoassay technologies in Europe, ranging from standard ELISA to multiplexed methods such as Luminex, SP-X or ELLA systems, or ultra-sensitive technologies such as MSD, Gyrolab or Simoa HD-X platforms. Website: active-biomarkers.com
About Vitruvian - Vitruvian is a leading international growth investor headquartered in London with additional offices in Stockholm, Madrid, Munich, Luxembourg, San Francisco, Singapore and Shanghai. Vitruvian focuses on dynamic situations characterized by rapid growth and change across industries. Vitruvian has backed over 90 companies and has assets under management of approximately €10 billion. Website: vitruvianpartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005063/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pure Lithium Opens New Chicago Headquarters, Advancing Commercialization of Its Lithium Metal Battery22.10.2025 19:24:00 CEST | Press release
Pure Lithium Corp., a disruptive vertically integrated lithium metal battery technology company, officially opened its new headquarters in Chicago’s Fulton Market district with a ribbon cutting ceremony Tuesday attended by community and business leaders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022239586/en/ From left: Ken Hoffman, Pure Lithium Special Advisor; Dr. Yuan Gao, Member of Pure Lithium Scientific Advisory Board; Derek Willis, Vice President of Commercial Development at Oxy Low Carbon Ventures and Pure Lithium Board Director; Miss Illinois Nitsaniyah Fitch; Chicago Mayor Brandon Johnson; Pure Lithium Founder, Chairman & CEO Emilie Bodoin; Illinois State Senator Lakesia Collins; Former Massachusetts Governor & Pure Lithium Board Director William F. Weld; Lisa Clemmons-Stott, Senior Economic Advisor, Director’s Office, Illinois Department of Commerce and Economic Opportunity The opening marks a milestone in
Doha Debates Launches New Debate Season with Al Jazeera22.10.2025 19:07:00 CEST | Press release
The new season brings global voices together for truth-seeking discussions Qatar Foundation’s Doha Debates launched a new season of its flagship program, Doha Debates, on October 21, co-produced with Al Jazeera Digital. The upcoming season features high-profile guests, bold global themes and a renewed focus on open, truth-seeking dialogue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022828303/en/ Qatar Foundation’s Doha Debates launches new debate season, bringing global voices together for truth-seeking discussions. (photo: AETOSWire) Airing weekly on Tuesdays through December 9, the eight-episode season explores three overarching themes—freedom, grand narratives and family. Each episode features leading thinkers and young changemakers engaging in timely conversations on the issues shaping humanity, ranging from meritocracy to social media; from love to architecture; from ancient traditions to the future of work. The
Picsart, Gen Z’s Preferred Digital Content Creation Platform, Takes LinkedIn Creators to Dracula’s Castle for “Why Your Marketing Sucks” Halloween Campaign22.10.2025 18:23:00 CEST | Press release
Picsart, the world’s leading digital creation platform, has announced the release of its new Halloween campaign and ebook, Why Your Marketing Sucks: a highly visual, tongue-in-cheek guide to the scariest mistakes marketers make and how to avoid them. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022722043/en/ Why Your Marketing Sucks Ebook by Picsart The campaign, running from October 15 through October 31, combines horror-themed storytelling with practical marketing advice and expertise. Its centerpiece, the Why Your Marketing Sucks ebook, was co-created by Picsart and five top LinkedIn marketing influencers during an exclusive brand trip to Transylvania to visit Bran Castle — thought to be the home of Count Dracula himself. Picsart’s COO and Co-Founder, Mikayel Vardanyan, said “Gen Z represents more than 25% of today’s workforce. Picsart has been supporting this demographic for 15 years — more than half of our users ar
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 202522.10.2025 18:00:00 CEST | Press release
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced that it will present new data from its proprietary Targeted Protein Degradation (TPD) and Proximity Inducer Platform (A-PROX) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held at the Hynes Convention Centerin Boston, MA, from October 22–26, 2025. Aurigene’s A-PROX platform integrates library screening, direct-to-biology chemistries, proprietary ternary complex assays, modelling algorithms, and structure-based design to accelerate the discovery and optimization of both protein degraders, molecular glues and proximity inducers. Through this integrated approach, Aurigene has advanced a strong pre-clinical portfolio of next-generation degraders, includinga SMARCA2-selective degrader, which recently received Investigational New Drug (IND) approval from the United States Food and Drug Administration (FDA); a pan-KRA
Visa Live Takes Flight with Benson Boone at the Rocket Garden22.10.2025 17:30:00 CEST | Press release
From le Louvre to the Launch Pad, Visa Live returns with another unforgettable music experience that puts fans at the center of the action. Prepare for lift-off this November as Visa presents another unforgettable cultural moment with Visa Live at the Rocket Gardenfeaturing global chart-topping sensation, Benson Boone on November 29. After the global success of Visa Live at le Louvre, the next chapter of the series lands at one of the world’s most iconic locations, the Rocket Garden at Kennedy Space Center Visitor Complex in Merritt Island, Florida. Headlined by Benson Boone, with a special guest to be announced, this event will be livestreamed on TikTok, inviting fans everywhere to join a night of music under the stars in a setting typically reserved for daylight exploration. “The Visa Live experience speaks to a fundamental truth in music: the space or environment in which the music is performed actually matters to both the artist and the audience,” said Frank Cooper III, Chief Marke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom